Biocon Innovation

Navigating the Complexities of Peaks and Attributes in Biopharmaceuticals Using Mass Spectrometry-based Multi-Attribute Method (MAM)

Summary: Biosimilars present unique development challenges, but the Mass Spectrometry-based Multi-Attribute Method (MAM) offers a deeper understanding of molecule attributes by analyzing multiple factors in a single workflow. This advanced technique ensures efficient analysis, reduces variability, and maintains the consistent quality and safety of biosimilars. Biological medicines (biopharmaceutical) have transformed the way we treat chronic … Continue reading Navigating the Complexities of Peaks and Attributes in Biopharmaceuticals Using Mass Spectrometry-based Multi-Attribute Method (MAM)

Biocon Global Bio India, Healthcare, Innovation

Global Bio India 2024: Biocon Group Playing a Critical Role in Realizing India’s Bioeconomy Potential

Biocon Group participated at the recently concluded Global Bio-India 2024 (GBI 2024), a Government of India initiative under the Department of Biotechnology. The 4th Edition of the GBI 2024, held during September 12-14 in New Delhi witnessed a large representation from key stakeholders in the biotechnology sector, demonstrating India’s biotech potential to the world. In … Continue reading Global Bio India 2024: Biocon Group Playing a Critical Role in Realizing India’s Bioeconomy Potential

Biocon General, Innovation, Women Empowerment

A Vision of ‘Viksit Bharat’, Driven by Inclusion & Innovation

By Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics In the Interim Union Budget 2024-25, Finance Minister Nirmala Sitharaman has provided a comprehensive roadmap for sustained economic growth that will enable India to achieve a developed economy status by 2047. The global economy went through a volatile period between 2020 and 2023. However, India’s GDP … Continue reading A Vision of ‘Viksit Bharat’, Driven by Inclusion & Innovation

Biocon Innovation, Tech Summit

Govt Support in Fundamental Research key to make India a truly knowledge based Economy

Know Bengaluru Tech Summit Bengaluru Tech Summit (BTS) is a platform for knowledge sharing, discussions, best industry practices, transformative insights and thought leadership to the stakeholders and participants, covering various gamut of technologies, innovation and entrepreneurship.   The three-day event was inaugurated by Karnataka Chief Minister Siddaramaiah on November 29, 2023, at the Bangalore Palace. … Continue reading Govt Support in Fundamental Research key to make India a truly knowledge based Economy

Biocon Healthcare, Innovation, Reputation

What Drives Corporate  Reputation of a Pharma Brand?  

What Drives Corporate  Reputation of a Pharma Brand?   A new film has released, and you can’t make up your mind whether it’s worth your time and money. What do you do?   Well, reading some reviews might help, or maybe a recommendation from a friend. In either instance, you decision would be based on the reputation … Continue reading What Drives Corporate  Reputation of a Pharma Brand?  

Biocon Biosimilar, Biosimilars, General, Healthcare, Innovation, Partnerships

The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw

Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw

Biocon Biosimilars, Innovation, Policy

Biosimilars Regulatory Framework Must Evolve in Line with Emerging Scientific Evidence

Dr. Sundar Ramanan, Global Head of Regulatory Affairs, Biocon Biologics Dr. Sundar Ramanan, Vice President & Head, Global Regulatory Affairs, Biocon Biologics, presented on behalf of the Company at the public meeting for the reauthorization process for the Biosimilar User Fee Act (BsUFA III) program organized by the U.S. Food and Drug Administration (FDA) on … Continue reading Biosimilars Regulatory Framework Must Evolve in Line with Emerging Scientific Evidence

Biocon Biosimilars, Innovation

Expanding Oncology Portfolio for the Benefit of Cancer Patients

We added another feather in our cap with the U.S. FDA approval of Fulphila™, biosimilar Pegfilgrastim co-developed with our partner Mylan. Fulphila™ is the first FDA-approved biosimilar Pegfilgrastim and the second biosimilar from Biocon and Mylan’s joint portfolio approved in the U.S. Pegfilgrastim is a long-lasting, pegylated form of recombinant granulocyte colony-stimulating factor that is … Continue reading Expanding Oncology Portfolio for the Benefit of Cancer Patients

Biocon Biosimilars, Innovation

Biocon’s Trastuzumab Journey: First biosimilar from India to be approved by U.S. FDA

December 2017 was a defining moment in our biosimilars journey when Biocon and partner Mylan became the first companies globally to receive U.S. Food and Drug Administration (FDA) approval for biosimilar Trastuzumab. Ogivri™ (trastuzumab-dkst) was the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S., and it made us the first Indian … Continue reading Biocon’s Trastuzumab Journey: First biosimilar from India to be approved by U.S. FDA